CN109259146A - One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application - Google Patents
One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application Download PDFInfo
- Publication number
- CN109259146A CN109259146A CN201810978415.4A CN201810978415A CN109259146A CN 109259146 A CN109259146 A CN 109259146A CN 201810978415 A CN201810978415 A CN 201810978415A CN 109259146 A CN109259146 A CN 109259146A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- inhibit
- application
- effects
- fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 34
- 230000000694 effects Effects 0.000 title claims abstract description 25
- 230000003902 lesion Effects 0.000 title claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 210000004185 liver Anatomy 0.000 claims abstract description 11
- 230000001580 bacterial effect Effects 0.000 claims abstract description 7
- 235000009200 high fat diet Nutrition 0.000 claims abstract description 6
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 5
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 5
- 238000009825 accumulation Methods 0.000 claims abstract description 5
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 5
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 5
- 230000006698 induction Effects 0.000 claims abstract description 5
- 208000019423 liver disease Diseases 0.000 claims abstract description 5
- 230000005976 liver dysfunction Effects 0.000 claims abstract description 5
- 244000005700 microbiome Species 0.000 claims abstract description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 5
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000006041 probiotic Substances 0.000 claims description 6
- 235000018291 probiotics Nutrition 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 235000020167 acidified milk Nutrition 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 235000021110 pickles Nutrition 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000005418 vegetable material Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 7
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/20—Products from fruits or vegetables; Preparation or treatment thereof by pickling, e.g. sauerkraut or pickles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application, bacterial strain is Lactobacillus rhamnosus Lactobacillus rhamnosus NCU2217, China Committee for Culture Collection of Microorganisms's common micro-organisms center is deposited on April 9th, 2018, address: Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, Institute of Microorganism, Academia Sinica, it is referred to as CGMCC, deposit number is CGMCC NO15573, the food of Lactobacillus rhamnosus and its preparation that the present invention uses, in the non-alcoholic fatty liver disease for adjusting high fat diet induction, it shows to inhibit liver dysfunction, reduce liver fat accumulation, improve the microstructure of fatty liver, promote the effect of hepatic injury reparation.
Description
Technical field
The invention belongs to microorganism fields, and being specifically related to one plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions
And its application.
Background technique
Lactobacillus rhamnosus is that Abroad in Recent Years studies a kind of more probiotic lactic acid bacteria, is widely present in traditional
In fermented dairy product and human gastrointestinal tract.It is very wide that existing great mass of data shows that Lactobacillus rhamnosus has in field of probiotic bacteria
Exploitation and application prospect.Result of study has confirmed that Lactobacillus rhamnosus has following prebiotic function: (1) antibacterial action at present.
According to the report, Lactobacillus rhamnosus is inhibited to some pathogenic bacteria in food and enteron aisle, it is antibacterial caused by fermentation
Substance has inhibiting effect to Gram-positive, negative bacterium and various pathogens；(2) antioxidation.Studies have shown that rhamnose
Bacteria suspension, cell-free extract and the exocellular polysaccharide of lactobacillus all have stronger antioxidant activity；(3) immunoregulation effect.
Lactobacillus rhamnosus can enhance the immune response of mouse intestinal and system, and to the delayed allergy of mouse cell,
Splenic lymphocytes competence for added value and NK cell activity also have remarkable result；(4) intestines problem is treated.But current rhamnose cream
Bacillus is not reported still the effect of alleviating in terms of colitis.
Summary of the invention
Have effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application the object of the present invention is to provide one plant.For
Realize object above, the present invention provides following technical schemes:
One plant have effects that inhibit fatty live lesions Lactobacillus rhamnosus and its application, bacterial strain be Lactobacillus rhamnosus
Lactobacillus rhamnosus NCU2217 is deposited in Chinese microorganism strain preservation management on April 9th, 2018
Committee's common micro-organisms center, address: Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, Chinese Academy of Sciences's microbe research
Institute, is referred to as CGMCC, and deposit number is CGMCC NO15573.
One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application: the Lactobacillus rhamnosus
Lactobacillus rhamnosus NCU2217 is the derivative of viable bacteria or inactivated bacteria or the bacterial strain.
One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application: the application is applied to food
Field, the food can be fermentation fruits and vegetables, acidified milk, cheese, milk-contained drink, milk powder or other contain the bacterial strain or the bacterium
Any one of the food of strain derivative.
One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application: described to have alleviation colitis function
Imitate specific manifestation are as follows: in the non-alcoholic fatty liver disease for adjusting high fat diet induction, show to inhibit liver dysfunction, reduce
Liver fat accumulation, the microstructure for improving fatty liver, the effect for promoting hepatic injury reparation.
One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application: the application are as follows: rhamnose cream
Bacillus forms composition in the form of food, the large fruits and vegetables of fermenting generate acid it is fresh it is palatable, full of nutrition, natural fruit and vegetables taste is strong simultaneously
Probiotics fermention fruit and vegetable food with good health-care efficacy, comprising: pickles, beverage, slurry, without adding any perfume (or spice) in product
These food additives of smart fragrance, pigment, acid, stabilizer, preservative, all flavors are produced by probiotics fermention fruit and vegetable materials
It is raw.
Beneficial effects of the present invention:
Lactobacillus rhamnosus CGMCC NO.11886 is in the non-alcoholic fatty liver disease for adjusting high fat diet induction, performance
Inhibit liver dysfunction, the microstructure for reducing liver fat accumulation, improving fatty liver, the effect for promoting hepatic injury reparation out.
Detailed description of the invention
Fig. 1 is influence of the Lactobacillus rhamnosus CGMCC NO15573 to Liver Function.
Fig. 2 is serum lipopolysaccharides and cellular immunity factor level.
Fig. 3 is influence of the Lactobacillus rhamnosus CGMCC NO15573 to Induced by High Fat Diet in Rats liver pathology.
Specific embodiment
Experimental example
With reference to the accompanying drawing with experimental example, test data, the present invention is specifically described:
Healthy SD rat, male, 120-150g are placed under feeding environment and adapt to 1 week.Rat is divided into normal group at random
(ND), hyperlipidemia model group (HFD), Lactobacillus rhamnosus CGMCC NO.11886 low dose group (108CFU/mL) and rhamnose cream
4 groups of bacillus CGMCC NO.11886 high dose group (109CFU/mL), every group 10.All rat normal waters, give model
Group, high dose group and low dose group high lipid food.According to 10mL/kg weight to high dose group and low dose group stomach-filling corresponding dosage
Lactobacillus rhamnosus CGMCC NO.11886, hyperlipidemia model group and normal group stomach-filling Isodose physiological saline, continuous 5 weeks.
After experiment, rat pierces through blood sampling, is centrifuged to obtain serum through chloral hydrate anesthesia, heart.Sterile colonic faecal, liver, fat,
Kidney etc. is spare.The calculation formula of liver and fat organs index are as follows: shoot formation=organ mass (g)/rat body weight (g) ×
100.Then using kit measurement serum glutamic pyruvic transminase (ALT) and glutamic-oxalacetic transaminease (AST) activity, total bilirubin is measured
The enzyme activities such as SOD, GSH-Px, CAT and MDA content are measured using enzyme linked immunological kit according to specification in content, serum
Serum lipopolysaccharides (LPS), interleukin (IL) -6, IL-10 and tumor necrosis factor (TNF)-alpha content.
Liver organization is taken to be placed in 10% formalin fixer fixed, using haematoxylin Yihong (hematoxylin
And eosin, H&E) dyeing progress pathological observation.Using gas chromatography measurement liver fat acid composition.
Table 1 is composition
Table 2 is influence of the Lactobacillus rhamnosus CGMCC NO.11886 to rat liver oxidative stress
Experimental result is shown in Figure of description 1,2,3 and subordinate list 1,2, the results show that Lactobacillus rhamnosus CGMCC
NO15573 shows to inhibit liver dysfunction, reduces liver rouge in the non-alcoholic fatty liver disease for adjusting high fat diet induction
Fat accumulation, the microstructure for improving fatty liver, the effect for promoting hepatic injury reparation.
Claims (5)
1. one plant have effects that inhibit fatty live lesions Lactobacillus rhamnosus and its application, bacterial strain be Lactobacillus rhamnosus
Lactobacillus rhamnosus NCU2217 is deposited in Chinese microorganism strain preservation management on April 9th, 2018
Committee's common micro-organisms center, address: Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, Chinese Academy of Sciences's microbe research
Institute, is referred to as CGMCC, and deposit number is CGMCC NO15573.
2. one plant according to claim 1 has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application,
Be characterized in that: the Lactobacillus rhamnosus Lactobacillus rhamnosus NCU2217 is viable bacteria or inactivated bacteria or should
The derivative of bacterial strain.
3. one plant according to claim 1 has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application,
Be characterized in that: the application is applied to field of food, and the food can be fermentation fruits and vegetables, acidified milk, cheese, drink containing cream
Material, milk powder or other contain any one of the bacterial strain or the food of the strain derivative.
4. one plant according to claim 1 has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application,
It is characterized in that: described that there is inhibition fatty live lesions specific manifestation are as follows: in the nonalcoholic fatty liver for adjusting high fat diet induction
In disease, shows to inhibit liver dysfunction, the microstructure for reducing liver fat accumulation, improving fatty liver, hepatic injury is promoted to repair
Multiple effect.
5. one plant according to claim 1 has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application,
It is characterized in that: the application are as follows: Lactobacillus rhamnosus forms composition in the form of food, and the large fruits and vegetables of fermenting generate that acid is fresh can
Mouth, full of nutrition, natural fruit and vegetables taste is strong and has the probiotics fermention fruit and vegetable food of good health-care efficacy, comprising: pickles, drink
Expect, slurry, without adding these food additives of any flavors and fragrances, pigment, acid, stabilizer, preservative, institute in product
There is flavor to be generated by probiotics fermention fruit and vegetable materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810978415.4A CN109259146B (en) | 2018-08-27 | 2018-08-27 | Application of lactobacillus rhamnosus in preparation of composition with fatty liver lesion inhibiting effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810978415.4A CN109259146B (en) | 2018-08-27 | 2018-08-27 | Application of lactobacillus rhamnosus in preparation of composition with fatty liver lesion inhibiting effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109259146A true CN109259146A (en) | 2019-01-25 |
| CN109259146B CN109259146B (en) | 2022-05-20 |
Family
ID=65154455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810978415.4A Active CN109259146B (en) | 2018-08-27 | 2018-08-27 | Application of lactobacillus rhamnosus in preparation of composition with fatty liver lesion inhibiting effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109259146B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109136130A (en) * | 2018-08-27 | 2019-01-04 | 南昌大学 | One plant of Lactobacillus rhamnosus NCU2217 |
| CN111154682A (en) * | 2020-01-16 | 2020-05-15 | 深圳市沁帆科技有限公司 | Lactobacillus rhamnosus, microbial agent and food product |
| WO2021137495A1 (en) * | 2020-01-02 | 2021-07-08 | 삼육대학교산학협력단 | Pharmaceutical composition for prevention or treatment of non-alcoholic fatty liver disease comprising butyricimonas sp. strain as active ingredient |
| CN114246310A (en) * | 2021-12-23 | 2022-03-29 | 红河宏斌食品有限公司 | Direct-vat probiotic fermented capsicum frutescens and preparation method thereof |
| CN114504083A (en) * | 2020-11-16 | 2022-05-17 | 烟台东宇海珍品有限公司 | Processing method of sea cucumber sausages |
| CN114717147A (en) * | 2022-03-23 | 2022-07-08 | 江南大学 | Metazoan prepared from Lactobacillus rhamnosus and used for relieving fatty liver and obesity, and application thereof |
| CN116676240A (en) * | 2023-07-28 | 2023-09-01 | 善恩康生物科技（苏州）有限公司 | Lactobacillus rhamnosus and application thereof in preventing or treating alcoholic liver disease |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102618456A (en) * | 2012-02-28 | 2012-08-01 | 江南大学 | Lactobacillus rhamnosus capable of relieving chronic alcohol liver injury and application thereof |
| US8298526B2 (en) * | 2010-06-02 | 2012-10-30 | Genmont Biotech Inc. | Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof |
| CN103898017A (en) * | 2014-03-28 | 2014-07-02 | 广西皇氏甲天下乳业股份有限公司 | Application of lactobacillus rhamnosus derived from longevity village in Bama of Guangxi in assisting in reducing blood fat |
| JP2014132890A (en) * | 2012-12-12 | 2014-07-24 | Shimane Prefecture | Lactobacillus having hepatic neutral fat decreasing action derived from brassica rapa (turnip) cv. tsuda |
| CN104305168A (en) * | 2014-07-29 | 2015-01-28 | 吉林农业大学 | A preparing method of lactobacillus rhamnosus particle food relieving alcoholic liver injury |
| CN104789488A (en) * | 2014-03-09 | 2015-07-22 | 黑龙江大学 | Lactobacillus rhamnosus having cholesterol lowering effect, and uses thereof |
| CN105400727A (en) * | 2015-12-21 | 2016-03-16 | 南昌大学 | Lactobacillus paracasei with antioxidant activity and application thereof |
| KR20160108751A (en) * | 2015-03-06 | 2016-09-20 | 경희대학교 산학협력단 | Novel lactic acid capable of controlling blood glucose level and use thereof |
| CN109136130A (en) * | 2018-08-27 | 2019-01-04 | 南昌大学 | One plant of Lactobacillus rhamnosus NCU2217 |
| CN109136131A (en) * | 2018-08-27 | 2019-01-04 | 南昌大学 | One plant has effects that alleviate the Lactobacillus rhamnosus of colitis and its application |
| CN109182166A (en) * | 2018-08-27 | 2019-01-11 | 南昌大学 | One plant has effects that the Lactobacillus rhamnosus of relief of constipation and its application |
| CN109401994A (en) * | 2018-08-27 | 2019-03-01 | 南昌大学 | One plant has effects that inhibit the Lactobacillus rhamnosus of hyperlipemia and its application |
| CN110468070A (en) * | 2019-08-19 | 2019-11-19 | 江南大学 | Lactobacillus rhamnosus CCFM1060, its fermented food and bacterial preparation process |
| CN110638843A (en) * | 2019-08-19 | 2020-01-03 | 江南大学 | Application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial inoculum, food and/or medicament |
| US20210052674A1 (en) * | 2017-09-28 | 2021-02-25 | Kobiolabs, Inc. | Composition for diagnosis and treatment of alcoholic liver disease, using change in short-chain fatty acid producing gut bacterial community |
-
2018
- 2018-08-27 CN CN201810978415.4A patent/CN109259146B/en active Active
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8298526B2 (en) * | 2010-06-02 | 2012-10-30 | Genmont Biotech Inc. | Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof |
| CN102618456A (en) * | 2012-02-28 | 2012-08-01 | 江南大学 | Lactobacillus rhamnosus capable of relieving chronic alcohol liver injury and application thereof |
| JP2014132890A (en) * | 2012-12-12 | 2014-07-24 | Shimane Prefecture | Lactobacillus having hepatic neutral fat decreasing action derived from brassica rapa (turnip) cv. tsuda |
| CN104789488A (en) * | 2014-03-09 | 2015-07-22 | 黑龙江大学 | Lactobacillus rhamnosus having cholesterol lowering effect, and uses thereof |
| CN103898017A (en) * | 2014-03-28 | 2014-07-02 | 广西皇氏甲天下乳业股份有限公司 | Application of lactobacillus rhamnosus derived from longevity village in Bama of Guangxi in assisting in reducing blood fat |
| CN104305168A (en) * | 2014-07-29 | 2015-01-28 | 吉林农业大学 | A preparing method of lactobacillus rhamnosus particle food relieving alcoholic liver injury |
| KR20160108751A (en) * | 2015-03-06 | 2016-09-20 | 경희대학교 산학협력단 | Novel lactic acid capable of controlling blood glucose level and use thereof |
| CN105400727A (en) * | 2015-12-21 | 2016-03-16 | 南昌大学 | Lactobacillus paracasei with antioxidant activity and application thereof |
| US20210052674A1 (en) * | 2017-09-28 | 2021-02-25 | Kobiolabs, Inc. | Composition for diagnosis and treatment of alcoholic liver disease, using change in short-chain fatty acid producing gut bacterial community |
| CN109136130A (en) * | 2018-08-27 | 2019-01-04 | 南昌大学 | One plant of Lactobacillus rhamnosus NCU2217 |
| CN109136131A (en) * | 2018-08-27 | 2019-01-04 | 南昌大学 | One plant has effects that alleviate the Lactobacillus rhamnosus of colitis and its application |
| CN109182166A (en) * | 2018-08-27 | 2019-01-11 | 南昌大学 | One plant has effects that the Lactobacillus rhamnosus of relief of constipation and its application |
| CN109401994A (en) * | 2018-08-27 | 2019-03-01 | 南昌大学 | One plant has effects that inhibit the Lactobacillus rhamnosus of hyperlipemia and its application |
| CN110468070A (en) * | 2019-08-19 | 2019-11-19 | 江南大学 | Lactobacillus rhamnosus CCFM1060, its fermented food and bacterial preparation process |
| CN110638843A (en) * | 2019-08-19 | 2020-01-03 | 江南大学 | Application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial inoculum, food and/or medicament |
Non-Patent Citations (6)
| Title |
|---|
| BOBAE KIM等: "Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
| GANG WANG等: "Bifidobacterium adolescentis and Lactobacillus rhamnosus alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways", 《FOOD & FUNCTION》 * |
| YVONNE RITZE等: "Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice", 《PLOS ONE》 * |
| 曹少锋等: "降脂益生菌调节胆固醇代谢改善小鼠非酒精性脂肪肝", 《中国微生态学杂志》 * |
| 梁娇娇等: "鼠李糖乳杆菌hsryfm 1301发酵乳改善大鼠非酒精性脂肪肝特性研究", 《中国乳品工业》 * |
| 陈大卫等: "鼠李糖乳杆菌hsryfm 1301发酵乳在非酒精性脂肪肝细胞模型中对人肝细胞L-02的益生作用", 《食品与发酵工业》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109136130A (en) * | 2018-08-27 | 2019-01-04 | 南昌大学 | One plant of Lactobacillus rhamnosus NCU2217 |
| WO2021137495A1 (en) * | 2020-01-02 | 2021-07-08 | 삼육대학교산학협력단 | Pharmaceutical composition for prevention or treatment of non-alcoholic fatty liver disease comprising butyricimonas sp. strain as active ingredient |
| CN111154682A (en) * | 2020-01-16 | 2020-05-15 | 深圳市沁帆科技有限公司 | Lactobacillus rhamnosus, microbial agent and food product |
| CN114504083A (en) * | 2020-11-16 | 2022-05-17 | 烟台东宇海珍品有限公司 | Processing method of sea cucumber sausages |
| CN114246310A (en) * | 2021-12-23 | 2022-03-29 | 红河宏斌食品有限公司 | Direct-vat probiotic fermented capsicum frutescens and preparation method thereof |
| CN114246310B (en) * | 2021-12-23 | 2023-11-03 | 红河宏斌食品有限公司 | Direct-feeding type probiotics fermented millet peppery and preparation method thereof |
| CN114717147A (en) * | 2022-03-23 | 2022-07-08 | 江南大学 | Metazoan prepared from Lactobacillus rhamnosus and used for relieving fatty liver and obesity, and application thereof |
| CN114717147B (en) * | 2022-03-23 | 2023-07-25 | 江南大学 | Post-natal element prepared from lactobacillus rhamnosus and used for relieving fatty liver and obesity and application thereof |
| CN116676240A (en) * | 2023-07-28 | 2023-09-01 | 善恩康生物科技（苏州）有限公司 | Lactobacillus rhamnosus and application thereof in preventing or treating alcoholic liver disease |
| CN116676240B (en) * | 2023-07-28 | 2023-10-31 | 善恩康生物科技（苏州）有限公司 | Lactobacillus rhamnosus and application thereof in preventing or treating alcoholic liver disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109259146B (en) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109259146A (en) | One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application | |
| CN101486986B (en) | Preparation of freeze-dried Lactobacillus acidophilus powder | |
| CN102399733B (en) | Lactobacillus johnsonii, microbial inoculum, application and premix thereof | |
| CN109136131A (en) | One plant has effects that alleviate the Lactobacillus rhamnosus of colitis and its application | |
| CN103598594B (en) | Application of lactobacillus plantarum in reducing blood fat and assisting fat-reducing | |
| CN109182166A (en) | One plant has effects that the Lactobacillus rhamnosus of relief of constipation and its application | |
| CN113498433B (en) | Composition for preventing, improving or treating obesity or fatty liver disease comprising leuconostoc citrate WiKim0104 | |
| CN105533544A (en) | Natural fruit and vegetable enzyme product | |
| CN102318806B (en) | Preparation method of probiotics fermented pumpkin and carrot vegetable powder | |
| CZ300143B6 (en) | Lactobacillus strain, its use and product containing thereof | |
| JP2010095465A (en) | Immunostimulating composition containing lactic acid bacterium | |
| CN109401994A (en) | One plant has effects that inhibit the Lactobacillus rhamnosus of hyperlipemia and its application | |
| KR20120100608A (en) | Lactobacillus sakei k101 having an activity for prevention and treatment of immune diseases and inflammatory diseases | |
| CN106359904A (en) | Application of lactobacillus reuteri in replacement of feed antibiotic | |
| JP7266110B2 (en) | Composition for prevention, improvement or treatment of obesity or fatty liver disease containing Weissella hellenica WIKIM0103 | |
| CN106635886A (en) | Method for reducing egg cholesterol by utilizing lactobacillus paracasei of bile salt producing hydrolase | |
| CN105661230A (en) | Probiotic functional beverage and probiotic food prepared from Lens culinaris by fermentation | |
| CN112544721A (en) | Milk tablet for promoting growth of vital essence and preparation method thereof | |
| KR101731992B1 (en) | Method for culturing lactic acid bacteria having improved immunoactivity and stability | |
| KR101396842B1 (en) | Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same | |
| CN102524794A (en) | Preparation method of serum cholesterol reduction Kluyveromyces marxianus freeze-dried powder | |
| CN105670959A (en) | Probiotic strain and application thereof | |
| CN104774783A (en) | Lactobacillus casei capable of reducing cholesterol and method for producing probiotic yogurt from same | |
| KR100910657B1 (en) | Novel Lactrobacillus buchneri and use thereof | |
| CN115851535A (en) | Lactobacillus rhamnosus WFP52 with function of regulating immunity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |